Sign in

    Farzin

    Senior Vice President and Biotechnology Equity Research Analyst at Jefferies

    Farzin Haque is a Senior Vice President and Biotechnology Equity Research Analyst at Jefferies, specializing in biotechnology sector analysis with a focus on companies such as Allakos and Vera. He covers several biopharmaceutical stocks, and his track record includes a 20% success rate and an average return of -40.8% on recommendations, according to platforms like TipRanks. Haque has held his SVP role at Jefferies in recent years, with no publicly documented previous employments found in search results. He holds significant sector expertise, but specific securities licenses or FINRA credentials are not publicly listed.

    Farzin's questions to Travere Therapeutics (TVTX) leadership

    Farzin's questions to Travere Therapeutics (TVTX) leadership • Q3 2024

    Question

    Farzin, on behalf of Maurie Raycroft at Jefferies, asked if data from the open-label extension would be included in the FSGS Type C meeting package and whether pre-specified analyses are considered sufficient or if more post-hoc work is needed.

    Answer

    SVP of Research and Development Dr. Bill Rote confirmed that open-label extension data from both the DUET and DUPLEX studies will be included. He stated they will present existing pre-specified analyses and will work with the FDA to align on any additional analyses required for the submission, rather than conducting extensive new post-hoc analyses beforehand.

    Ask Fintool Equity Research AI